## Johnson & Johnson Innovation – JLABS @ TMC

Rachel Rath, MBA, MPH Director, BARDA Alliance Interim Head JLABS @ TMC

Johnson Johnson innovation JLABS



January 12, 2023

## More than 130 years of creating value through innovation

Business Segments Ĝ \$14.7₿

Invested in R&D in 2021

Selling products in more than

175

countries



People use our products worldwide everyday

Johnson&Johnson innovation




03 04 04 Flor (Thiamph.

KK (BIV 3928) 22 in Transporte Media PMT activity

Advancing New Healthcare Solutions through Collaboration

Johnson Johnson innovation



(17

### Acceleration

### Incubation

### Collaborations

### Deep R&D expertise


Investments

## 360° global innovation capabilities

Through our regional teams, life science and health technology innovators have access to the breadth and depth of offerings that are unique to Johnson & Johnson.

Johnson Johnson INNOVATION





#### **Europe, Middle East & Africa**

#### Other Locations

The Netherlands

Tel Aviv, Israel

#### **Asia Pacific**

**APAC Innovation** Center Shanghai, China

JLABS @ Shanghai Shanghai, China

#### Other Locations

Hong Kong Japan Singapore South Korea

### Early Innovation Partnering

### Incubation & Acceleration

### Venture Investment

- 4 Innovation Centers in life science hubs
- Networks connecting ecosystems to create flexible collaborations, deals and investments
- ~680+ collaborations\*
- \$2.1B+ in collaboration capital deployed since 2013\*
- Deep scientific & commercial expertise

(Johnson Johnson INNOVATION

- 13 locations across the globe connecting residents into a vibrant innovation ecosystem, state-of-theart lab amenities, offices and equipment
- 840+ companies supported since inception with 290+ having at least one deal and/or partnership with J&J
- 30% female-led companies, 30% minority-led companies

- Oldest corporate healthcare VC nearly 50 years of experience
- Investing at all stages of innovation, from seed funding to Series A and bevond
- 160+ active portfolio companies
- Co-creation of new companies
- \$3.5B+ in capital distributed across companies and funds since 2013\*†

+Includes capital calls and tranches

### Late Stage **Partnerships**


 Licensing, M&A expertise and alliance management, embedded across all business segments 40+ years of leading licensing and M&A deals, working with companies at all stages of development

# Incubation & acceleration with JLABS

- Locations across the globe connecting residents into a vibrant innovation ecosystem, state-of-the-art lab amenities, offices and equipment
- 840+ portfolio companies since inception with 290+ having at least one deal and/or partnership with a J&J company\*
- 30% female-led companies, 30% minority-led companies



# A comprehensive model to accelerate innovation





## No-strings-attached




Get started fast without significant funding



Know-how & connections to be partner ready



Get to go/no-go decisions sooner



Johnson Johnson innovation JLABS



## The JLABS difference

**13** JLABS sites across the globe

100+

Investment firms engaged through our Investor Hub

#### 836+ Portfolio Companies (current & alumni)

**571** 

Pharmaceuticals

- 159

**Medical** Devices

<mark>५</mark> 106

**Consumer Health** 



Cross-sector

**\$63.7B** Financing & Strategic Relationships (secured & contingent)

47 Publicly traded

38 Companies acquired

270 JLABS companies with at least 1 deal with Johnson & Johnson

Johnson Johnson INNOVATION JLABS



## Johnson & Johnson Innovation -JLABS companies make headlines

The biotech unicorns are back: Alector burnishes its \$1.3B valuation in an IPO that generates \$176M in cash

Black-Owned Businesses Acclinate and K'ept Health Make Most of JLABS Resources – Johnson & Johnson Innovation's D.C. Incubator Helps Startups that Target Health Disparities

#### J&J bets up to \$780M on Cidara's Universal Influenza Treatment

Huma: This start-up doubled the reach of some UK hospitals during Covid — and investors are taking note

Neuron23 uncloaks with \$113.5M to tackle CNS disorders through genetic mutations Forbes Asia 100 to watch – NDR andUs2.ai

Arcturus: Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021

San Diego's Locanabio raises \$100 million for treatments aimed at degenerative diseases Sheena Franklin takes on culturallycompetent skin health page 8

UPHEALTH.COM

LTHMOONSHOTS.COM



Meet the Health Transformers

Start Up Health Annual Vintage Updates

2021 Midyear Insights Report

Health Transformers in the News



Thank you to all our applicants of the Washington, DC Health Innovation QuickFire Challenge,

43% Serial entrepreneurs

**31%** Female-led companies

30% Minority-led companies

Johnson formon innovation JLABS

#### 57% First-time entrepreneurs

## JLABS @ TMC

**115** Portfolio Companies (current & alumni)

**•** 66

**公 37 以 12** 



**Pharmaceuticals** 

**Medical** Devices

**Consumer Health** 

**Cross-sector** 

**\$3.8B** Financing & Strategic Relationships (secured & contingent)

Publicly 6 traded

Companies 3 acquired

JLABS companies with at least 1 deal with Johnson & Johnson 27





### Selection Criteria & Process

- 1. Submit non-confidential company information
- Undergo internal Johnson & Johnson selection 2. process
- Notification of accept or reject 3.

Johnson Johnson innovation jlabs

Compelling science and/or technology





Ability to meet the financial obligations of the license agreement





Credible science/ technology team





#### Area of significant medical or market need





Crowdsourcing innovation to seek out and inspire innovators addressing great unmet medical need aligned with Johnson & Johnson's strategic areas of interest.

Awardees may receive grant funding, access to world-class lab facilities, programs and resources, and mentorship from industry experts.

Learn more and discover the latest opportunities at http://jji.jnj/challenges.

Johnson Johnson innovation JLABS



## QuickFire Challenge

To date, Johnson & Johnson Innovation has:

# [][**\$** \$15M+

Awarded in prizes



named worldwide







Challenges Launched

## Collaborating through publicprivate partnerships



Dedicated to anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements with the aim to prepare for and respond to our rapidly evolving global health environment.









## Priority Areas for Partnering

## Areas of interest across our 3 business segments

Solution Pharmaceuticals		C MedTech	Second
Immunology Neuroscience Cardiovascular, Metabolism, Retina & Pulmonary Hypertension	Oncology Infectious Diseases & Vaccines Discovery, Product Development & Supply Data Science	MedTech Vision	Essential C Self Care Skin Health

**N** Integrated Healthcare Solutions

Lung Cancer Initiative

World Without Disease Accelerator

#### sumer Health

#### Care

th

### #MakeTheConnection

- Meet up at local, regional and global partnering events
- Contact us and submit your ideas through our online challenges
- Engage with us and our collaborators through social media
- Explore our website and get to know our leadership
- Visit our locations across the globe

Email us rrath4@its.jnj.com



(മ)

Follow us on Twitter @JNJInnovation



Visit our website for more information jnjinnovation.com



Subscribe to our e-newsletters jnjinnovation.com/subscribe



Apply for a QuickFire Challenge jnjinnovation.com/innovation-challenges

Johnson-Johnson innovation